Trinity Biotech | TRIB - Cash And Equivalent


Trinity Biotech reported $1.34M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 7.51B 560M Sep/2025
Bayer EUR 5.9B 1.34B Sep/2025
Bio-Rad Laboratories USD 395.8M 26.5M Sep/2025
EDAP TMS EUR 29.84M 4.35M Dec/2024
J&J USD 18.23B 10.35B Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Siemens EUR 14.64B 1.96B Jun/2025
Thermo Fisher Scientific USD 9.85B 7.87B Dec/2025
Tosoh JPY 133.1B 10.44B Sep/2025
Trinity Biotech USD 1.34M 3.83M Sep/2025
Veracyte USD 315.57M 96.07M Sep/2025